AIM: In this study, we sought to evaluate the utility of actigraphy for examining symptoms of rapid eye movement sleep behaviour disorder (RSBD). METHODS: Twenty-two patients with idiopathic Parkinson's Disease (mean age=63.4 years, SD=7.5) underwent neurological assessment and completed sleep diaries, self-report sleep questionnaires and 2-weeks of actigraphy. They also completed the rapid eye movement sleep behavior disorder questionnaire and were classified as screening negative (RSBD-, n=9) or positive (RSBD+, n=13) for RSBD according to published criteria. Key outcome data were the number of wake bouts and duration of arousals during the sleep interval as determined by actigraphy. RESULTS: Patients classified as RSBD+ demonstrated a higher number of wake bouts than those who were RSBD- (p=0.011). CONCLUSIONS: These results suggest that actigraphy may be a viable tool to assist in the early identification of RSBD. In turn, this could guide early intervention approaches. Copyright 2010 Elsevier B.V. All rights reserved.
AIM: In this study, we sought to evaluate the utility of actigraphy for examining symptoms of rapid eye movement sleep behaviour disorder (RSBD). METHODS: Twenty-two patients with idiopathic Parkinson's Disease (mean age=63.4 years, SD=7.5) underwent neurological assessment and completed sleep diaries, self-report sleep questionnaires and 2-weeks of actigraphy. They also completed the rapid eye movement sleep behavior disorder questionnaire and were classified as screening negative (RSBD-, n=9) or positive (RSBD+, n=13) for RSBD according to published criteria. Key outcome data were the number of wake bouts and duration of arousals during the sleep interval as determined by actigraphy. RESULTS:Patients classified as RSBD+ demonstrated a higher number of wake bouts than those who were RSBD- (p=0.011). CONCLUSIONS: These results suggest that actigraphy may be a viable tool to assist in the early identification of RSBD. In turn, this could guide early intervention approaches. Copyright 2010 Elsevier B.V. All rights reserved.
Authors: D M Wallace; S Shafazand; D Z Carvalho; F B Nahab; C Sengun; A Russell; H P Moore; C Singer Journal: J Clin Neurol Date: 2012-03-31 Impact factor: 3.077
Authors: Ian B Hickie; Sharon L Naismith; Rébecca Robillard; Elizabeth M Scott; Daniel F Hermens Journal: BMC Med Date: 2013-03-22 Impact factor: 8.775
Authors: George Zhong; Samuel Bolitho; Ronald Grunstein; Sharon Linda Naismith; Simon John Geoffrey Lewis Journal: PLoS One Date: 2013-08-21 Impact factor: 3.240
Authors: Samuel J Bolitho; Sharon L Naismith; Pierre Salahuddin; Zoe Terpening; Ron R Grunstein; Simon J G Lewis Journal: PLoS One Date: 2013-11-21 Impact factor: 3.240